Skip to main content
Top
Published in: Familial Cancer 4/2008

01-12-2008

Cascade genetic testing for mismatch repair gene mutations

Authors: R. J. Mitchell, R. K. Ferguson, A. Macdonald, M. G. Dunlop, H. Campbell, M. E. Porteous

Published in: Familial Cancer | Issue 4/2008

Login to get access

Abstract

Mismatch repair gene mutation carriers have a high risk of developing colorectal cancer, and can benefit from appropriate surveillance. A combined population based ascertainment cascade genetic testing approach provides a systematic and potentially effective strategy for identifying such carriers. We have developed a Markov Chain computer model system which simulates various factors influencing cascade genetic testing; including demographics, uptake, genetic epidemiology and family size. This was used to evaluate cascade genetic testing for mismatch repair gene mutations in theory and practice. Simulations focussed on the population of Scotland by way of illustration, and were based on a 20-year programme in which index cases were ascertained from colorectal cancer cases aged <55 years at onset. Results indicated that without practical barriers to cascade genetic testing, 545 (95% CI = 522, 568) carriers could be identified; 42% of the population total. This comprised approximately 140 index cases, 302 asymptomatic relatives and 104 previously affected relatives. However, when realistic ascertainment and acceptance rates were used to inform simulations, only 257 (95% CI = 246, 268) carriers, about 20% of the carrier population, were identifiable. Of these approximately 112 were index cases, 108 were asymptomatic relatives, and 37 were previously affected relatives. This contrast emphasises the importance of ascertainment and acceptance rates. Likewise the low number of index cases shows that case identification is a limiting factor. In the absence of robust data from epidemiological studies, these findings can inform decisions about the use of cascade genetic testing for mismatch repair gene mutations.
Appendix
Available only for authorised users
Literature
1.
go back to reference Aaltonen LA, Salovaara R, Kristo P et al (1998) Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 338:1481–1487PubMedCrossRef Aaltonen LA, Salovaara R, Kristo P et al (1998) Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 338:1481–1487PubMedCrossRef
2.
go back to reference Aarnio M, Sankila R, Pukkala E et al (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81:214–218PubMedCrossRef Aarnio M, Sankila R, Pukkala E et al (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81:214–218PubMedCrossRef
3.
go back to reference Dunlop MG, Farrington SM, Carothers AD et al (1997) Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 6:105–110PubMedCrossRef Dunlop MG, Farrington SM, Carothers AD et al (1997) Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 6:105–110PubMedCrossRef
4.
go back to reference Liu B, Farrington SM, Petersen GM et al (1995) Genetic instability occurs in the majority of young patients with colorectal cancer. Nat Med 1:348–352PubMedCrossRef Liu B, Farrington SM, Petersen GM et al (1995) Genetic instability occurs in the majority of young patients with colorectal cancer. Nat Med 1:348–352PubMedCrossRef
5.
go back to reference Lynch HT, de la Chapelle A (1999) Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 36:801–818PubMed Lynch HT, de la Chapelle A (1999) Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 36:801–818PubMed
6.
go back to reference Vasen HF, Wijnen JT, Menko FH et al (1996) Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110:1020–1027PubMedCrossRef Vasen HF, Wijnen JT, Menko FH et al (1996) Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110:1020–1027PubMedCrossRef
7.
go back to reference Mitchell RJ, Farrington SM, Dunlop MG et al (2002) Mismatch repair genes hMLH1 and hMSH2 and colorectal cancer: a HuGE review. Am J Epidemiol 156:885–902PubMedCrossRef Mitchell RJ, Farrington SM, Dunlop MG et al (2002) Mismatch repair genes hMLH1 and hMSH2 and colorectal cancer: a HuGE review. Am J Epidemiol 156:885–902PubMedCrossRef
8.
go back to reference Jarvinen HJ, Aarnio M, Mustonen H et al (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118:829–834PubMedCrossRef Jarvinen HJ, Aarnio M, Mustonen H et al (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118:829–834PubMedCrossRef
9.
go back to reference Dunlop MG, Farrington SM, Nicholl I et al (2000) Population carrier frequency of hMSH2 and hMLH1 mutations. Br J Cancer 83:1643–1645PubMedCrossRef Dunlop MG, Farrington SM, Nicholl I et al (2000) Population carrier frequency of hMSH2 and hMLH1 mutations. Br J Cancer 83:1643–1645PubMedCrossRef
10.
go back to reference Brown ML, Kessler LG (1996) Use of gene tests to detect hereditary predisposition to cancer: what do we know about cost effectiveness? Int J Cancer 69:55–57PubMedCrossRef Brown ML, Kessler LG (1996) Use of gene tests to detect hereditary predisposition to cancer: what do we know about cost effectiveness? Int J Cancer 69:55–57PubMedCrossRef
11.
go back to reference Coughlin SS, Miller DS (1999) Public health perspectives on testing for colorectal cancer susceptibility genes. Am J Prev Med 16:99–104PubMedCrossRef Coughlin SS, Miller DS (1999) Public health perspectives on testing for colorectal cancer susceptibility genes. Am J Prev Med 16:99–104PubMedCrossRef
12.
go back to reference Ponder BA (1999) Costs, benefits and limitations of genetic testing for cancer risk. Br J Cancer 80 suppl 1:46–50PubMed Ponder BA (1999) Costs, benefits and limitations of genetic testing for cancer risk. Br J Cancer 80 suppl 1:46–50PubMed
13.
go back to reference Terdiman JP, Conrad PG, Sleisenger MH (1999) Genetic testing in hereditary colorectal cancer: indications and procedures. Am J Gastroenterol 94:2344–2356PubMedCrossRef Terdiman JP, Conrad PG, Sleisenger MH (1999) Genetic testing in hereditary colorectal cancer: indications and procedures. Am J Gastroenterol 94:2344–2356PubMedCrossRef
14.
go back to reference Welch HG, Burke W (1998) Uncertainties in genetic testing for chronic disease. JAMA 280:1525–1527PubMedCrossRef Welch HG, Burke W (1998) Uncertainties in genetic testing for chronic disease. JAMA 280:1525–1527PubMedCrossRef
15.
go back to reference Krawczak M, Cooper DN, Schmidtke J (2001) Estimating the efficacy and efficiency of cascade genetic screening. Am J Hum Genet 69:361–370PubMedCrossRef Krawczak M, Cooper DN, Schmidtke J (2001) Estimating the efficacy and efficiency of cascade genetic screening. Am J Hum Genet 69:361–370PubMedCrossRef
16.
go back to reference Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ et al (2001) Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 357:165–168PubMedCrossRef Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ et al (2001) Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 357:165–168PubMedCrossRef
17.
go back to reference Bhatnagar D, Morgan J, Siddiq S et al (2000) Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ 321:1497–1500PubMedCrossRef Bhatnagar D, Morgan J, Siddiq S et al (2000) Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ 321:1497–1500PubMedCrossRef
18.
go back to reference Marks D, Wonderling D, Thorogood M et al (2002) Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ 324:1303–1307PubMedCrossRef Marks D, Wonderling D, Thorogood M et al (2002) Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ 324:1303–1307PubMedCrossRef
19.
go back to reference Hadfield GS, Humphries SE (2007) Familial hypercholesterolaemia: cascade testing is tried and tested and cost effective. BMJ 335:683PubMedCrossRef Hadfield GS, Humphries SE (2007) Familial hypercholesterolaemia: cascade testing is tried and tested and cost effective. BMJ 335:683PubMedCrossRef
20.
go back to reference Lerman C, Hughes C, Trock BJ et al (1999) Genetic testing in families with hereditary nonpolyposis colon cancer. JAMA 281:1618–1622PubMedCrossRef Lerman C, Hughes C, Trock BJ et al (1999) Genetic testing in families with hereditary nonpolyposis colon cancer. JAMA 281:1618–1622PubMedCrossRef
21.
go back to reference Quehenberger F, Vasen HF, van Houwelingen HC (2005) Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet 42:491–496PubMedCrossRef Quehenberger F, Vasen HF, van Houwelingen HC (2005) Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet 42:491–496PubMedCrossRef
22.
go back to reference Chamberlain J, Smallwood S (2004) Estimates of true birth order for Scotland, 1945–1999. Popul Trends 117:27–42PubMed Chamberlain J, Smallwood S (2004) Estimates of true birth order for Scotland, 1945–1999. Popul Trends 117:27–42PubMed
23.
go back to reference Morris JK (2004) Is cascade testing a sensible method of population screening? J Med Screen 11:57–58PubMedCrossRef Morris JK (2004) Is cascade testing a sensible method of population screening? J Med Screen 11:57–58PubMedCrossRef
24.
go back to reference Vasen HF, Mecklin JP, Khan PM et al (1991) The International Collaborative Group on hereditary non-polyposis colorectal cancer [ICG-HNPCC]. Dis Colon Rectum 34:424–425PubMedCrossRef Vasen HF, Mecklin JP, Khan PM et al (1991) The International Collaborative Group on hereditary non-polyposis colorectal cancer [ICG-HNPCC]. Dis Colon Rectum 34:424–425PubMedCrossRef
25.
go back to reference Jenkins MA, Hayashi S, O’Shea A-M et al (2007) Pathology features in Bethesda guidelines predict microsatellite instability: a population-based study. Gastroenterology 133:48–56PubMedCrossRef Jenkins MA, Hayashi S, O’Shea A-M et al (2007) Pathology features in Bethesda guidelines predict microsatellite instability: a population-based study. Gastroenterology 133:48–56PubMedCrossRef
26.
go back to reference Barnetson RA, Tenesa A, Farrington SM et al (2006) Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 354:2751–2763PubMedCrossRef Barnetson RA, Tenesa A, Farrington SM et al (2006) Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 354:2751–2763PubMedCrossRef
27.
go back to reference Aktan-Collan K, Mecklin JP, Jarvinen H et al (2000) Predictive genetic testing for hereditary non-polyposis colorectal cancer: uptake and long-term satisfaction. Int J Cancer 89:44–50PubMedCrossRef Aktan-Collan K, Mecklin JP, Jarvinen H et al (2000) Predictive genetic testing for hereditary non-polyposis colorectal cancer: uptake and long-term satisfaction. Int J Cancer 89:44–50PubMedCrossRef
28.
go back to reference Aktan-Collan K, Mecklin JP, de la Chapelle A, Peltomaki P, Uutela A, Kaariainen H (2000) Evaluation of a counselling protocol for predictive genetic testing for hereditary non-polyposis colorectal cancer. J Med Genet 37:108–113PubMedCrossRef Aktan-Collan K, Mecklin JP, de la Chapelle A, Peltomaki P, Uutela A, Kaariainen H (2000) Evaluation of a counselling protocol for predictive genetic testing for hereditary non-polyposis colorectal cancer. J Med Genet 37:108–113PubMedCrossRef
29.
go back to reference Ponz de Leon M, Benatti P, Di Gregorio C et al (2004) Genetic testing among high-risk individuals in families with hereditary nonpolyposis colorectal cancer. Br J Cancer 90:882–887PubMedCrossRef Ponz de Leon M, Benatti P, Di Gregorio C et al (2004) Genetic testing among high-risk individuals in families with hereditary nonpolyposis colorectal cancer. Br J Cancer 90:882–887PubMedCrossRef
30.
go back to reference Dunlop MG (2002) Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polypolis, juvenile polyposis, and Peutz-Jeghers syndrome. Gut 51 suppl 5:V21–V27PubMedCrossRef Dunlop MG (2002) Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polypolis, juvenile polyposis, and Peutz-Jeghers syndrome. Gut 51 suppl 5:V21–V27PubMedCrossRef
Metadata
Title
Cascade genetic testing for mismatch repair gene mutations
Authors
R. J. Mitchell
R. K. Ferguson
A. Macdonald
M. G. Dunlop
H. Campbell
M. E. Porteous
Publication date
01-12-2008
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 4/2008
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-008-9192-x

Other articles of this Issue 4/2008

Familial Cancer 4/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine